InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$294.66

2026-10-16

Market Cap

$113.0B

Volume

3.4M

52-Wk High

$392.55

52-Wk Low

$267.00

Trailing PE

30.3

P/S

4.37

Gross Margin

65.2%

Net Margin

14.4%

ROE

16%

ROIC

10%

Piotroski

8/9

Altman Z

4.6

1-Yr Return

-20.2%

5-Yr Return

+44.5%

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

SectorHealthcareIndustryMedical - DevicesExchangeNYSEMarket Cap$113.0BEmployees56,000 (SEC-filed)CEOKevin A. LoboIPO1980-03-17CountryUS

1941 Stryker Way, Portage, MI 49002 · Tel 269 385 2600 · stryker.com

INSIDERSTREET SCORE74 / 100Street mean $357.83 (12 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$219M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · SYK -20.2% · S&P 500 +15.9% · spread -36.1pp

7 Years vs S&P 500 · SYK +44.5% · S&P 500 +189.9% · spread -145.3pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE74of 100

Score Breakdown

Profitability	72/100
Growth	64/100
Momentum	90/100
Quality	87/100
Earnings Quality	78/100
Balance Sheet	63/100
Value	52/100
Risk (safety)	100/100
Overall	73.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MDT	64
ABT	57
BSX	67
EW	65
DXCM	81
ZBH	60
SYK	74

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 74 in 26 Q2, latest 74 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY74 / 100IS Score 73.6 / 100 · +0.0 from peak of 74

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 69 / 100 · Power +38 · 17 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 74 and price structure at 69 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 73.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 59 → 67 → 69 → 74	the direction matters more than the level
Technical vote share back above 50%	now 73%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,332 → now 2,277	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)1330 up / 1018 downnet +312 funds

Institutions Added (13F)-37managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 2,332 · latest 2,277 (-55 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,277	309.9M	$93.5B	80.8%
2026 Q1	2,314	299.3M	$94.0B	78.0%
2025 Q4	2,332	304.2M	$102.2B	79.3%
2025 Q3	2,275	297.5M	$105.1B	77.6%
2025 Q2	2,263	306.0M	$114.5B	79.8%
2025 Q1	2,236	303.7M	$107.9B	79.2%
2024 Q4	2,201	299.1M	$103.1B	78.0%
2024 Q3	2,040	299.6M	$103.2B	78.1%
2024 Q2	1,993	295.0M	$95.5B	76.9%
2024 Q1	2,000	294.4M	$99.8B	76.8%
2023 Q4	1,890	293.9M	$83.6B	76.6%
2023 Q3	1,780	293.8M	$76.4B	76.6%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Wells Preston Wendell	VP, Chief Financial Officer	2026-09-24	J-Other	109	—	3,661
Wells Preston Wendell	VP, Chief Financial Officer	2026-09-22	J-Other	962	—	3,770
Baculik Emily Kay	VP, Corporate Controller	2026-09-01	—	805	$0.20M	0
Baculik Emily Kay	VP, Corporate Controller	2026-09-01	—	1,490	$0.40M	0
Baculik Emily Kay	VP, Corporate Controller	2026-09-01	—	1,265	$0.43M	0
Baculik Emily Kay	VP, Corporate Controller	2026-09-01	—	918	$0.36M	0
Baculik Emily Kay	VP, Corporate Controller	2026-09-01	—	1,060	$0.38M	0
Crotty Dylan Bram	Group President	2026-08-21	SELL	441	$0.14M	6,102

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	36	674,531	$218.9M	Counted
M — Exercises (paired A/D)	8	24,538	$3.6M	None — mechanics
F — Tax withholding	14	69,158	$22.5M	None — compensation
G — Gifts	1	1,607	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$218.9M36 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-18	Debra King	826	$0.3M
2026-08-17	Stryker Ronda E	350,000	$117.2M
2026-05-28	Fletcher Robert S	4,544	$1.4M
2026-05-27	Stryker Ronda E	310,000	$97.0M
Trailing 12 mo	9 filings	1,188,536	$402M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	6.73%	25.8M sh
2026-04-14	SCHEDULE 13D/A	STRYKER RONDA E	4.00%	15.2M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-02-11	SCHEDULE 13G/A	GREENLEAF TRUST	4.40%	16.8M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-25	2026-10-09
Ro Khanna	House	SELL	$15,001 - $50,000	2026-09-11	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Alan Armstrong	Senate	SELL	$15,001 - $50,000	2026-03-27	2026-07-21
Dan Sullivan	Senate	SELL	$1,001 - $15,000	2022-11-30	2023-07-26
Dan Sullivan	Senate	SELL	$1,001 - $15,000	2022-11-30	2023-07-25

House 12-Mo27 trades6 purchases

Senate 12-Mo1 trades0 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,314

13F Shares299M78.0% of shares out

New / Closed168 / 145positions, QoQ

Increased / Reduced944 / 886positions, QoQ

Put/Call (13F)1.09option positions

Free Float90.8%348M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fenimore Asset Management Inc	550,558	$152M
Fort Washington Investment Advisor	367,335	$101M
Perpetual Ltd	338,569	$93M
Davenport & Co Llc	285,110	$79M
Cws Financial Advisors, Llc	241,684	$67M
Td Waterhouse Canada Inc.	208,609	$57M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$3.0B
VTSAX	0.1%	$3.0B
VTI	0.1%	$3.0B
VSMPX	0.1%	$3.0B
VFIAX	0.1%	$2.5B
VOO	0.1%	$2.5B

13F Filers Holding SYK — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session63.6%2026-10-15

20-Day Avg51.8%50-day 50.7%

TrendRising20d vs 50d

By Market CenterQ: 63% · N: 73% · B: 61%latest session

Weekly Notional ($B)

Where SYK Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	2.7M	32 sh
Ubsa Ubs Ats	2.3M	33 sh
Sgmt Sigma X2	1.6M	33 sh
Ebxl Level Ats	1.3M	23 sh
Bids Bids Ats	0.9M	265 sh
Mlix Instinct X	0.9M	42 sh

Where a dollar of Stryker Corporation revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
EMEA	$3.2B	52%
Asia Pacific	$2.2B	35%
Other foreign countries	$765M	13%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SYK (live moat model)Peer median: MDT · ABT · BSX · EW · DXCM

Component scores from the live moat model. Peer median illustrative.

Moat score 64/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Kevin A. Lobo	Chairman & CEO
Spencer S. Stiles	President & COO
J. Andrew Pierce	Group President of MedSurg & Neurotechnology
Preston Wells	Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)2 of 6recent quarters

Avg Surprise+0.5%

Next Report2026-10-29

Income Quality1.48OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+19.2%	+7.8%	+11.1%	+10.2%	+11.2%
Gross profit	+22.3%	+3.1%	+13.2%	+11.9%	+14.9%
Operating income	+24.3%	-0.8%	+14.6%	+18.2%	-3.4%
Net income	+24.7%	+18.3%	+34.2%	-5.4%	+8.5%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	17.1	18.4	20.5	22.6	25.1
Cost of revenue	6.4	7.4	8.0	8.6	9.1
Gross profit	10.7	11.0	12.5	14.0	16.1
R&D expense	1.1	1.2	1.3	1.4	1.6
SG&A expense	5.8	6.1	6.9	7.5	8.7
Operating income	3.8	3.7	4.3	5.1	4.9
EBITDA	3.6	4.0	5.1	4.9	6.3
D&A	1.0	1.0	1.0	1.1	1.2
Pretax income	2.3	2.7	3.7	3.5	4.5
Income tax	0.3	0.3	0.5	0.5	1.3
Net income	2.0	2.4	3.2	3.0	3.2
Diluted EPS ($)	5.22	6.17	8.25	7.76	8.40
Diluted shares (M)	382	382	384	386	382

Operating CF$5B

CapEx$1B

Free cash flow$4B

SBC$0B

Buybacks$0B

Net cash change$0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.8	3.0	3.7	4.0
ST investments	0.1	0.1	0.8	0.1
Receivables (net)	3.6	3.8	4.0	4.0
Total current assets	10.3	12.5	14.8	14.8
PP&E (net)	3.4	3.7	4.0	3.9
Goodwill + intangibles	19.8	19.8	20.2	25.0
Total assets	36.9	39.9	43.0	47.8
Accounts payable	1.4	1.5	1.7	0.0
Short-term debt	1.3	2.2	1.6	0.0
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	6.3	7.9	7.6	7.8
Long-term debt	11.9	10.9	12.2	14.9
Total liabilities	20.3	21.3	22.3	25.4
Shareholders' equity	16.6	18.6	20.6	22.4

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	2.4	3.2	3.0	3.2
D&A	1.0	1.0	1.1	1.2
Stock-based compensation	0.2	0.2	0.2	0.2
Working capital change	(0.7)	(0.5)	(0.7)	(0.4)
Operating cash flow	2.6	3.7	4.2	5.0
Capital expenditures	(0.6)	(0.6)	(0.8)	(0.8)
Investing cash flow	(2.9)	(1.0)	(3.0)	(4.9)
Buybacks	(0.1)	(0.2)	(0.2)	0.0
Dividends paid	(1.1)	(1.1)	(1.2)	(1.3)
Debt issuance / (repay)	0.5	(0.3)	0.9	1.6
Financing cash flow	(0.7)	(1.6)	(0.5)	0.1
Free cash flow	2.0	3.1	3.5	4.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	14.3%	15.0%	18.0%	15.3%	15.1%	16%
ROA	5.8%	6.6%	8.2%	7.2%	7.1%	7.8%
ROIC	12.9%	11.6%	12.9%	14.3%	12.2%	9.8%
Gross margin	62.6%	59.8%	61.0%	61.9%	64.0%	65.2%
Operating margin	22.0%	20.2%	20.9%	22.4%	19.5%	22.0%
Net margin	11.7%	12.8%	15.4%	13.2%	12.9%	14.4%
EBITDA margin	21.1%	21.8%	24.7%	21.9%	25.1%	25.9%
FCF margin	16.0%	11.0%	15.3%	15.4%	17.1%	—
VALUATION
P/E	49.35	38.60	35.75	46.14	41.85	30.3
P/B	6.61	5.48	6.09	6.69	6.06	4.7
P/S	5.75	4.93	5.52	6.11	5.41	4.37
P/FCF	35.94	44.70	36.08	39.60	31.72	24.0
EV/EBITDA	30.04	27.88	26.29	32.52	24.85	18.6
EV/Revenue	6.33	5.56	6.03	6.54	5.84	4.8
Earnings yield	2.0%	2.6%	2.8%	2.2%	2.4%	3.30%
FCF yield	2.8%	2.2%	2.8%	2.5%	3.2%	4.16%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	2.20	1.63	1.58	1.95	1.89	2.16
Quick ratio	1.47	1.00	0.97	1.32	1.21	1.33
Debt / equity	0.87	0.81	0.73	0.68	0.66	0.62
Debt / assets	37.3%	36.7%	33.8%	32.9%	31.1%	31.2%
Net debt / EBITDA	2.74	3.15	2.22	2.12	1.82	1.73
Interest coverage	—	—	—	—	6.72	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.50	0.52	0.53	0.55	0.55	0.54
Receivables turnover	5.98	5.60	5.59	5.83	6.26	6.9
DSO (days)	61	65	65	63	58	53
DPO (days)	55	62	67	67	33	67
Cash conversion cycle	198	182	200	197	226	209
GROWTH (YoY)
Revenue growth	19.2%	7.8%	11.1%	10.2%	11.2%	—
Net income growth	24.7%	18.3%	34.2%	-5.4%	8.5%	—
EPS growth	24.2%	18.4%	33.7%	-6.0%	8.3%	—
FCF growth	-1.9%	-25.6%	54.0%	11.2%	22.8%	—
PER SHARE ($)
EPS (diluted, TTM)	5.21	6.17	8.24	7.75	8.40	9.72
Book value / share	38.87	43.46	48.43	53.44	58.01	62.55
Revenue / share	44.70	48.26	53.39	58.52	64.98	67.37
FCF / share	7.15	5.33	8.17	9.03	11.08	12.26
Cash / share	7.89	5.04	7.95	11.64	10.61	9.06
SHAREHOLDER RETURN & SCORES
Buyback yield	0.1%	0.1%	0.1%	0.1%	0.1%	0.13%
Altman Z-Score	4.47	4.12	4.73	5.31	4.23	4.6
Piotroski F-Score	8	7	7	7	7	8/9
Beneish M-Score	-2.56	-2.29	-2.51	-2.56	-2.60	-2.74

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	4.6	Safe (>2.99)	Safe
Income quality	1.48	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.74	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.72
Interest burden	0.95
Operating margin	21.1%
Asset turnover	0.55×
Financial leverage	2.09×
= ROE	17%

Growth Quality (live)	Value
Revenue stability	0.99
Earnings stability	0.81
Earnings persistence	0.89
Revenue CAGR 3y	9.9%
EPS CAGR 3y	11.0%
FCF CAGR 3y	24.8%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.13%

Dividend Yield1.19%

Total Shareholder Return1.21%cash yield

SBC / Revenue1.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MDT	$121.2B	23.2	11%	15.1%	+9.8%	9/9	+3.0%
ABT	$181.5B	33.7	11%	7.4%	+8.1%	5/9	-17.8%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	+19.2%
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	—
ZBH	$18.1B	23.0	6%	9.1%	+8.6%	6/9	—
PEN	$12.6B	78.4	11%	8.9%	+17.6%	6/9	—
SNN	$12.2B	19.0	22%	9.8%	+11.5%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

52 Analysts

Str Sell (0)Sell (0)Hold (15)Buy (36)Str Buy (1)

Mean Target (qtr)$357.8312 targets

Target vs. Price+21.4%last-quarter mean

Next Report2026-10-29street $3.55

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$27.18B	$27.39B / $26.91B	$14.96	$15.06 / $14.90	16
FY2027	$29.53B	$29.93B / $28.70B	$16.68	$17.15 / $16.12	16
FY2028	$31.86B	$32.49B / $31.16B	$18.59	$19.39 / $17.41	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$332.75	+12.9%	4
Last Quarter	$357.83	+21.4%	12
Last Year	$387.73	+31.6%	41
All Time	$356.11	+20.9%	97

Rolling mean of published targets vs. last close $294.66. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

4/5

ROE

4/5

ROA

5/5

Debt/Eq

1/5

P/E

2/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

SYK -20.2% vs S&P 500 +15.9% — spread -36.1pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$278.22	+16.44	+5.91%	Above
SMA 50	$299.75	-5.09	-1.70%	Below
SMA 200	$326.51	-31.85	-9.75%	Below
EMA 9	$284.77	+9.89	+3.47%	Above
EMA 21	$283.67	+10.99	+3.87%	Above
EMA 50	$293.85	+0.81	+0.28%	Above
EMA 200	$321.75	-27.09	-8.42%	Below

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +3817 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%56

Momentum 25%91

Volume 20%75

Volatility 10%67

Patterns 15%50

This Week73% bullishof 11 price-based votes

4 Weeks Ago0%+73 pts since

12 Weeks Ago18%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$278.22

Price vs SMA 50$299.75

Price vs SMA 200$326.51

EMA 9/21 Cross284.8/283.7

SMA 50/200Death

ADX DirectionADX 21

Supertrend$296

Parabolic SAR$273

SMA Slope1.020

RSI58.9

Stochastic K/D83/80

StochRSI K/D98/98

Williams %R-18

CCI253

TSI vs Signal-6.3

CMO17.8

ROC6.99%

OBV SignalAccum

Chaikin MF-0.040

MFI56

Force Index5M

Elder Ray Bull16.00

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 80

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$291.26 / $295.96 / $298.70	S1 / S2	$288.52 / $283.82
Bollinger (20,2)	$265.05 – $291.39	Squeeze	Off
52-wk range	$267.00 – $392.55	Off 52-wk high	-24.9%
ATR (14)	$8.02 (2.7%)	Historical vol	24.9%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+4.1%Jan75%

+0.3%Feb60%

+0.1%Mar62%

+1.7%Apr50%

+0.8%May60%

-0.2%Jun40%

-0.0%Jul45%

+0.9%Aug65%

+0.9%Sep55%

+0.8%Oct50%

+1.5%Nov75%

+1.8%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	SYK	S&P 500
Weekly volatility (σ, 1y)	4.55%	1.83%
Best / worst week (1y)	+13.9% / -13.5%	—
Max drawdown (5y, monthly)	-37.9%	—
1-week VaR (95%)	-9.4%	—
Beta (5y)	0.77	1.00

SYK EQUITY WEATHER (LIVE)CLOUDY · -4

Trend-38

Momentum+48

Volume+36

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 278 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-4.3+15.9 vs industry

Trend-38.2-16.0 vs industry

Momentum+48.0+70.0 vs industry

Volume+35.8+40.8 vs industry

Reading	SYK	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	-4.3	-20.2	-24.0	-20.5
Trend	-38.2	-22.1	-25.6	-21.3
Momentum	+48.0	-22.0	-28.5	-15.8
Volume	+35.8	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Kevin A. Lobo Chair, Chief Executive Officer	$21.4M	56% equity+incentive
Spencer S. Stiles Group President, Orthopaed	$6.3M	54% equity+incentive
J. Andrew Pierce Group President, MedSurg an	$6.3M	54% equity+incentive
Preston W. Wells Vice President, Chief Finan	$4.4M	53% equity+incentive
Viju S. Menon Group President, Global Qualit	$4.2M	53% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	67
Social	58
Governance	64
Composite ESG	63

Composite ESG Trend

Filed	8-K contents	Items
2026-10-06	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-07-30	Earnings Release; Exhibits	2.02,9.01
2026-06-26	Other Events; Exhibits	8.01,9.01
2026-05-20	Officer/Director Change; Exhibits	5.02,9.01
2026-05-08	Shareholder Vote	5.07
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-04-09	Regulation FD	7.01
2026-03-23	Regulation FD; Exhibits	7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-07-30
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-19 to 2026-09-24
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-02-11 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Stryker Corporation (SYK)

Institutions holding — 12 quarters

Stryker Corporation (SYK)

Monthly Net Insider Flow (000 shares)

Signal Summary

Stryker Corporation (SYK)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding SYK — quarterly

Institutional Put/Call — quarterly

Stryker Corporation (SYK)

Where SYK Trades in the Dark

Stryker Corporation (SYK)

3.8 · Employees (SEC filings)

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Balance Sheet — Full

Cash Flow Statement — Full

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Street Price Target — Trajectory

Third-Party Composite Rating

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Family Scores (site weights)

Stryker Corporation (SYK)

Stryker Corporation (SYK)

Stryker Corporation (SYK)